To see all protocols that comply with the WHO Essential Medicine List 
 Oesophageal varices:

This treatment is associated with an increased risk of fatal gastro-oesophageal variceal bleeding. Patients must be evaluated for the presence of varices and have them treated as indicated within 6 months prior to initiating this treatment. This treatment should be avoided in patients with varices that are untreated, actively bleeding (including recent bleeding) or at high risk of bleeding, or in patients who have not been assessed for varices within 6 months.

Treatment must be initiated and supervised by specialist physicians experienced in the treatment of cancer using immunological agents. Before commencing immunotherapy treatment in any patient, clinicians should have an understanding of the immune-related adverse events (irAEs) associated with immunotherapy treatment and their management.

This treatment should be initiated in consultation with a multidisciplinary team including a gastroenterologist and medical oncologist.

Check for clinical trials in this patient group. Link to Australian Clinical Trials website

From 1 June 2021 Avastin® (bevacizumab) will no longer be available on the PBS, and Mvasi® a biosimilar brand of bevacizumab will be the sole brand available on the PBS. The rapid infusion administration instructions for subsequent doses of bevacizumab included in eviQ protocols are based on studies conducted using Avastin® (bevacizumab).

The information contained in this protocol is based on the highest level of available evidence and consensus of the eviQ reference committee regarding their views of currently accepted approaches to treatment. Any clinician (medical oncologist, haematologist, radiation oncologist, medical physicist, radiation therapist, pharmacist or nurse) seeking to apply or consult this protocol is expected to use independent clinical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. While eviQ endeavours to link to reliable sources that provide accurate information, eviQ and the Cancer Institute NSW do not endorse or accept responsibility for the accuracy, currency, reliability or correctness of the content of linked external information sources. Use is subject to eviQ’s disclaimer available at www.eviQ.org.au

Send feedback for this page


First approved:
Review due:

The currency of this information is guaranteed only up until the date of printing, for any updates please check:

https://www.eviq.org.au/p/3881

23 Sep 2021